STRYKER CORP is expected to release its Q3 2026 10-Q filing on October 28, 2026, after market close. Last quarter: Stryker Corporation achieved strong second-quarter FY2026 performance with revenue increasing 9.4% YoY to $6.59B and net earnings rising 44.3% YoY to $1.28B, boosted by broad volume growth and tariff relief.
EPS Estimate
$3.52
Revenue Estimate
$6.65B
Analyst consensus from Finnhub. Actual results posted within minutes of the SEC filing on the SYK page.
Drawn from management commentary in the Q2 2026 10-Q:
Consolidated net sales grew 9.4% YoY (9.0% in constant currency) to $6.59B in Q2 FY2026. MedSurg and Neurotechnology net sales rose 9.7% to $3.63B, while Orthopaedics net sales rose 9.1% to $2.96B. U.S. sales grew 8.9% to $4.96B and International sales grew 11.0% to $1.63B.
Gross profit margin reached 68.3% in Q2 FY2026 compared to 63.8% in Q2 FY2025. The expansion was primarily driven by a 260 basis point benefit from the reversal of 2025 import tariffs and a 110 basis point benefit from lower amortization of inventory stepped up to fair value.
During Q1 FY2026, Stryker created the Ortho Tech business by combining orthopaedic instruments from Instruments with Other Orthopaedics. Neuro Cranial and Enabling Technologies were moved into Instruments to align with internal reporting structures, with prior periods restated accordingly.
Revenue
$6.59B
+9.42% YoY
EPS (Diluted)
$3.30
+44.10% YoY
Gross Margin
68.3%
+4.5 pts YoY
Operating Income
$1.66B
+49.06% YoY
Add SYK to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.